FORMULARY AND MANAGED ENTRY SUBGROUP

FMESG Statement on Rebate Schemes

GMMMG Greater Manchester Medicines Management Group NHS

The GMMMG Formulary and Managed Entry Subgroup (FMESG) is aware of the increasing number of rebate or other schemes being offered to CCGs and Trusts by the Pharmaceutical Industry for new or existing medicines.

The FMESG **does not** consider any such schemes when making decisions around formulary inclusion or approval. All decisions are clinically led and are made using the best available evidence, taking into consideration the following factors: clinical need, clinical effectiveness, cost effectivess, drug safety and affordability. The subgroup will promote treatments for which there is good evidence of clinical effectiveness in improving the health status of patients. A decision making tool is used to ensure consistency in decision making and rebate schemes are not included within the criteria included. The subgroup will not recommend a treatment that is shown to be ineffective or which cannot be shown to be effective i.e. where evidence is lacking or inconclusive.

GMMMG has endorsed the Good Practice Guidance on Rebate Schemes document which lists key criteria for consideration by organisations when entering into a rebate or other such schemes. Schemes may be assessed against the proposed criteria by the main GMMMG group; however this is carried out independently to any clinical decisions. Whilst some schemes may fulfil the criteria for approval this does not mean that the rebate scheme will be adopted. This is a local organisational decision to make and not that of GMMMG.

GMMMG Formulary and Managed Entry Subgroup
May 2017